Neuroendocrine tumors: A European view☆
References (27)
- et al.
Substance P-like immunoreactivity in carcinoid tumours (abstr)
Regul Pept
(1983) - et al.
Insulinoma: current diagnosis and surgical management
Curr Probl Surg
(1976) - et al.
MEA type I gastrinomas are extrapancreatic (abstr)
Regul Pept
(1984) Gut hormones and gut endocrine tumour syndromes
Br J Hosp Med
(1980)- et al.
Endocrine system
- et al.
The incidence of gut endocrine tumours in Ireland (abstr)
Dig Dis Sci
(1984) - et al.
Frequency of gastrointestinal endocrine tumours in Northern Ireland
Gut
(1986) - et al.
Characterisation of immunoreactive forms of pancreatic polypeptide (PP) in islet cell tumours
Cancer
(1985) - et al.
Insulinomas in N. Ireland 1960–1980-review of 16 cases
Ulster Med J
(1981) - et al.
Pancreatic polypeptide (PP): a potential marker for carcinoid tumours (abstr)
Dig Dis Sci
(1984)
Pancreatic polypeptide (PP) levels may be an indicator of responsiveness to streptozotocin in gastrointestinal (GI) endocrine tumours (abstr)
Dig Dis Sci
Metastatic pancreatic vipoma: a case report of clinical response following treatment with corticosteroids and actinomycin D
Clin Oncology
Evaluation of SMS 201-995 in gastrointestinal APUDomas
Scand J Gastroenterol
Cited by (144)
Incidence and prognosis of patients with small intestinal neuroendocrine tumors in a population based nationwide study
2022, Cancer EpidemiologyCitation Excerpt :Overall, 31% of our patients underwent acute or semi-acute surgery which led to the diagnosis of SI-NET which is in line with the above-mentioned Swedish study [5]. These results are in contrast with previous studies from the UK where almost none were diagnosed preoperatively [20,21]. Curative treatment of neuroendocrine tumors is exclusively surgical, whereas biotherapy with somatostatin analogues and interferon is good symptomatic therapy [1,2,17].
Pancreatic neuroendocrine tumours. What do we know of their history?
2016, Gastroenterologia y HepatologiaProteins differentially expressed in human beta-cells-enriched pancreatic islet cultures and human insulinomas
2013, Molecular and Cellular EndocrinologyCitation Excerpt :These important differences in the cytokine-induced response in rodent and human beta-cells urge caution when we directly translate the research results obtained in rodents to the human disease etiology and therapy. Insulinomas are the most common pancreatic endocrine neoplasms, representing approximately 17% of all neuroendocrine tumors of the digestive tract (Buchanan et al., 1986), constituting rare tumors, with an incidence of four patients per million inhabitants a year (Boden, 1989; Oberg and Eriksson, 2005; Tucker et al., 2006). Most insulinomas originate in individuals with a mean age of 50 years, being usually small (less than 2 cm), solitary and almost always benign (more than 90% of cases) (Boden, 1989; Oberg and Eriksson, 2005; Proye, 1987).
Epidemiology of gastroenteropancreatic neuroendocrine tumours
2012, Best Practice and Research: Clinical GastroenterologyCitation Excerpt :Other national cancer registries reporting GEP-NET incidence originate from Norway, Sweden, Ireland, Netherlands, Denmark, Scotland and the United Kingdom [10,11,20,21,28–31]. Some of these national registries report incidence for all NET (including bronchial) [29,30], or for all ‘carcinoids’ [20,21,31], while others report on incidence by anatomic site [10,11,28]. National registries dedicated to NET patients that are not population based, like those from Germany, France, Spain and recently from Italy are an important source of data on the epidemiology of GEP-NET, but unfortunately are unable to report on incidence rates of these tumours [13,16,19,22].
Metastatic risk of diminutive rectal carcinoid tumors: A need for surveillance rectal ultrasound?
2012, Gastrointestinal Endoscopy
- ☆
This work was supported by a grant from the Ulster Cancer Foundation.
- 1
Mr. John Collins is a Royal Victoria Hospital Research Fellow.